1
|
Kubo S, Oda H, Tanaka M, Koikeda T, Tomita S. Effects of Lactoferrin on Oral and Throat Conditions under Low Humidity Environments: A Randomized, Double-Blind, and Placebo-Controlled Crossover Trial. Nutrients 2023; 15:4033. [PMID: 37764816 PMCID: PMC10537525 DOI: 10.3390/nu15184033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2023] [Revised: 09/15/2023] [Accepted: 09/16/2023] [Indexed: 09/29/2023] Open
Abstract
To evaluate the effects of a single ingestion of bovine lactoferrin (bLF) on oral and throat conditions under a low-humidity environment. A randomized, double-blind, 2-sequence, 2-treatment, and 2-period placebo-controlled crossover trial was conducted. Healthy adult subjects orally ingested bLF dissolved in water, or placebo water, followed by exposure to low humidity (20 °C, 20% relative humidity (RH)) for 2 h. The primary endpoint was subjective oral and throat discomfort assessed by a visual analog scale (VAS), which positively correlated with the discomfort. Secondary endpoints were unstimulated whole salivary flow rate (UWSFR) and salivary immunoglobulin A (IgA) secretion rate. Overall, 40 subjects were randomly assigned to two sequences (20 each) and 34 were analyzed. The VAS values for oral and throat discomfort in the bLF treatment were significantly lower than in the placebo treatment, whereas UWSFR and IgA secretion rates were comparable between the two treatments. Adverse drug reactions were not observed. Subjective oral and throat discomfort associated with low humidity is suppressed by a single ingestion of bLF. Our findings demonstrate the novel use of bLF in a clinical situation that leverages its unique characteristics.
Collapse
Affiliation(s)
- Shutaro Kubo
- Innovative Research Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama 252-8583, Japan
| | - Hirotsugu Oda
- Innovative Research Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama 252-8583, Japan
| | - Miyuki Tanaka
- Innovative Research Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83 Higashihara, Zama 252-8583, Japan
| | - Takashi Koikeda
- Shiba Palace Clinic, Daiwa A Hamamatsucho Bldg. 6F, 1-9-10 Hamamatsucho, Minato 105-0013, Japan
| | - Shinichi Tomita
- Department of Advanced Food Sciences, Faculty of Agriculture, Tamagawa University, 6-1-1 Tamagawa-Gakuen, Machida 194-8610, Japan
| |
Collapse
|
2
|
Oda H, Kubo S, Tada A, Yago T, Sugita C, Yoshida H, Toida T, Tanaka M, Kurokawa M. Effects of Bovine Lactoferrin on the Maintenance of Respiratory and Systemic Physical Conditions in Healthy Adults-A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients 2023; 15:3959. [PMID: 37764743 PMCID: PMC10537451 DOI: 10.3390/nu15183959] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 09/07/2023] [Accepted: 09/12/2023] [Indexed: 09/29/2023] Open
Abstract
OBJECTIVES We investigated the effects of bovine lactoferrin (LF) on the maintenance of the respiratory and systemic physical conditions. METHODS A randomized, double-blind, placebo-controlled trial was conducted. Healthy adults at Kyushu University of Health and Welfare ingested a placebo or bovine LF (200 mg/day) for 12 weeks. The primary endpoints were the total respiratory and systemic symptom scores. The secondary endpoint was the activity of plasmacytoid dendritic cells (pDCs) in peripheral blood. RESULTS A total of 157 subjects were randomized (placebo, n = 79; LF, n = 78), of whom, 12 dropped out. The remaining 145 participants were included in the full analysis set (placebo group, n = 77; LF group, n = 68). The total scores for respiratory and systemic symptoms during the intervention were significantly lower in the LF group than in the placebo group. The expression of CD86 and HLA-DR on pDCs was significantly higher in the LF group than in the placebo group at week 12. Adverse events were comparable between the groups, and no adverse drug reactions were observed. CONCLUSIONS These results suggest that orally ingested LF supports the normal immune system via maintaining pDC activity, and maintains respiratory and systemic physical conditions in healthy adults.
Collapse
Affiliation(s)
- Hirotsugu Oda
- Innovative Research Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, Japan
| | - Shutaro Kubo
- Innovative Research Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, Japan
| | - Asuka Tada
- International BtoB Business Department, International Division, Morinaga Milk Industry Co., Ltd., 5-33-1, Shiba, Minato 108-8384, Japan
| | - Takumi Yago
- Innovative Research Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, Japan
| | - Chihiro Sugita
- Department of Biochemistry, Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare, 1714-1, Yoshino, Nobeoka 882-8508, Japan
| | - Hiroki Yoshida
- Department of Biochemistry, Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare, 1714-1, Yoshino, Nobeoka 882-8508, Japan
| | - Tatsunori Toida
- School of Pharmaceutical Sciences, Kyushu University of Health and Welfare, 1714-1, Yoshino, Nobeoka 882-8508, Japan
| | - Miyuki Tanaka
- Innovative Research Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 5-1-83, Higashihara, Zama 252-8583, Japan
| | - Masahiko Kurokawa
- Department of Biochemistry, Graduate School of Clinical Pharmacy, Kyushu University of Health and Welfare, 1714-1, Yoshino, Nobeoka 882-8508, Japan
| |
Collapse
|
3
|
Matsumoto T, Nakajima Y, Kubo S, Fukunaga M, Saito S, Hara H. Multicenter registry of the Watchman left atrial appendage closure device for patients with atrial fibrillation in Japan: The TERMINATOR registry. Eur Heart J 2023. [DOI: 10.1093/eurheartj/ehac779.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Private grant(s) and/or Sponsorship. Main funding source(s): Boston Scientific Japan
Background
Transcatheter left atrial appendage closure (LAAC) provides an alternative to oral anticoagulation for thromboembolic risk reduction in patients with nonvalvular atrial fibrillation (AF). A meta-analysis of previous two randomized trials reported improved rates of hemorrhagic stroke, cardiovascular/unexplained death, and nonprocedural bleeding compared to warfarin (1). Recently, the next-generation LAAC device, the Watchman FLX system, became available, and showed a low incidence of adverse events and a high incidence of anatomic closure (2). This transcatheter stroke prevention has already been approved in Asian countries. However, there is little data of LAAC in Asian population.
Purpose
This study sought to assess efficacy and safety of LAAC for patients with nonvalvular AF in Asia.
Methods
The TERMINATOR (Transcatheter Modification of Left Atrial Appendage by Obliteration with Device) registry is a multicenter nonrandomized study in Japan. This enrolled patients who underwent LAAC in 23 Japanese institutions. The LAAC was indicated for patients with nonvalvular atrial fibrillation in whom oral anticoagulation is required, but who have a risk of bleeding (history of BARC type 3 bleeding or HAS-BLED score ≥3 points). Baseline patient and procedural characteristics and clinical outcomes were evaluated.
Results
A total of 729 patients were enrolled between September 2019 and November 2021. The mean age was 74.9±8.8 years and the mean CHA2DS2-VASc score was 4.7±1.5. The Watchman generation 2.5 and FLX system were used in 469 (64.3%) and 260 patients (35.7%), respectively. Procedural success was achieved in 722 patients (99.0%). In-hospital adverse events were as follows; 6 tamponades (0.8%), 3 pericardial effusion (0.4%), 2 device embolization (0.3%), no stroke (0%), and no death (0%). During follow-up, device-related thrombus and all-cause death were reported in 16 (2.2%) and 23 patients (3.2%), respectively.
Conclusions
LAAC with the Watchman system provides compatible efficacy and safety outcomes in Asian population.
Collapse
Affiliation(s)
- T Matsumoto
- Shonan Kamakura General Hospital, Department of Cardiology and Catheterization Laboratories , Kamakura , Japan
| | - Y Nakajima
- Iwate University Hospital, Division of Cardiology, Department of Internal Medicine , Iwate , Japan
| | - S Kubo
- Kurashiki Central Hospital, Department of Cardiology , Kurashiki , Japan
| | - M Fukunaga
- Kokura Memorial Hospital, Department of Cardiology , Kokura , Japan
| | - S Saito
- Shonan Kamakura General Hospital, Department of Cardiology and Catheterization Laboratories , Kamakura , Japan
| | - H Hara
- Toho University Ohashi Medical Center, Division of Cardiovascular Medicine , Tokyo , Japan
| |
Collapse
|
4
|
Yamamoto M, Kubo S, Hirama N, Teranishi S, Tashiro K, Seki K, Maeda C, Hiro S, Kajita Y, Sugimoto C, Segawa W, Nagayama H, Nagaoka S, Kudo M, Kaneko T. 1089P Hepcidin expression as a predictive biomarker for anti-PD1/PDL1 antibody monotherapy for advanced non-small cell lung cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
5
|
Tan D, Kim Y, Lim MC, Sho M, Lu CH, Nagao S, Kubo S, Kim BG, Chen LT, Kanai M, Wang PH, Rha S, Ramar R, Wong M, Sasaki T. 101P Real-world prevalence of MSI-H/dMMR across 6 different tumor types in Asia. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
6
|
Nakamoto S, Taira N, Kawada K, Takabatake D, Miyoshi Y, Kubo S, Suzuki Y, Yamamoto M, Ogasawara Y, Yoshitomi S, Hara K, Shien T, Iwamoto T, Ohsumi S, Ikeda M, Mizota Y, Yamamoto S, Doihara H. 176P The effectiveness of long-term physical activity after exercise and educational programs on breast cancer-related lymphoedema: Secondary analyses from a randomized controlled trial: The Setouchi Breast Project 10. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
7
|
Kubo S, Miyakawa M, Tada A, Oda H, Motobayashi H, Iwabuchi S, Tamura S, Tanaka M, Hashimoto S. Lactoferrin and its digestive peptides induce interferon-α production and activate plasmacytoid dendritic cells ex vivo. Biometals 2022; 36:563-573. [PMID: 36018422 PMCID: PMC10181974 DOI: 10.1007/s10534-022-00436-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 08/15/2022] [Indexed: 11/25/2022]
Abstract
Plasmacytoid dendritic cells (pDCs) recognise viral single-stranded RNA (ssRNA) or CpG DNA via Toll-like receptor (TLR)-7 and TLR9, and produce interferon (IFN)-α. Activated pDCs upregulate human leukocyte antigen (HLA)-DR and CD86 expression levels. Ingestion of bovine lactoferrin (LF) activates pDCs, but little is known about its effects. In this study, the effects of LF and its pepsin hydrolysate (LFH) on the production of IFN-α from peripheral blood mononuclear cells (PBMCs) and pDCs were examined. PBMCs were prepared from peripheral blood of healthy adults and incubated with LF, LFH, or lactoferricin (LFcin) in the absence or presence of ssRNA derived from human immunodeficiency virus. The concentration of IFN-α in the supernatant and the expression levels of IFN-α, HLA-DR, and CD86 in pDCs were quantified by enzyme-linked immunosorbent assay and flow cytometry. In the absence of ssRNA, the concentration of IFN-α was negligible and LF had no effect on it. In the presence of ssRNA, IFN-α was detected at a certain level, and LF and LFH significantly increased its concentration. The increase caused by LFH and LFcin were comparable. In addition, LF significantly upregulated the expression levels of IFN-α, HLA-DR, and CD86 in pDCs. LF and its digestive peptides induced IFN-α production and activated pDCs in the presence of ssRNA, suggesting that LF modulates the immune system by promoting pDC activation upon viral recognition.
Collapse
Affiliation(s)
- Shutaro Kubo
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 1-83, 5, Higashihara, Zama, Kanagawa, Japan.
| | - Momoko Miyakawa
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 1-83, 5, Higashihara, Zama, Kanagawa, Japan
| | - Asuka Tada
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 1-83, 5, Higashihara, Zama, Kanagawa, Japan
| | - Hirotsugu Oda
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 1-83, 5, Higashihara, Zama, Kanagawa, Japan
| | - Hideki Motobayashi
- Second Department of Surgery, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, Japan
| | - Sadahiro Iwabuchi
- Department of Molecular Pathophysiology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, Japan
| | - Shinobu Tamura
- Department of Hematology/Oncology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, Japan
| | - Miyuki Tanaka
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd., 1-83, 5, Higashihara, Zama, Kanagawa, Japan
| | - Shinichi Hashimoto
- Department of Molecular Pathophysiology, Wakayama Medical University, 811-1 Kimiidera, Wakayama, Wakayama, Japan
| |
Collapse
|
8
|
Petty A, Glass LJ, Rothmond DA, Purves-Tyson T, Sweeney A, Kondo Y, Kubo S, Matsumoto M, Weickert CS. Increased levels of a pro-inflammatory IgG receptor in the midbrain of people with schizophrenia. J Neuroinflammation 2022; 19:188. [PMID: 35841099 PMCID: PMC9287858 DOI: 10.1186/s12974-022-02541-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2022] [Accepted: 06/22/2022] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND There is growing evidence that neuroinflammation may contribute to schizophrenia neuropathology. Elevated pro-inflammatory cytokines are evident in the midbrain from schizophrenia subjects, findings that are driven by a subgroup of patients, characterised as a "high inflammation" biotype. Cytokines trigger the release of antibodies, of which immunoglobulin G (IgG) is the most common. The level and function of IgG is regulated by its transporter (FcGRT) and by pro-inflammatory IgG receptors (including FcGR3A) in balance with the anti-inflammatory IgG receptor FcGR2B. Testing whether abnormalities in IgG activity contribute to the neuroinflammatory abnormalities schizophrenia patients, particularly those with elevated cytokines, may help identify novel treatment targets. METHODS Post-mortem midbrain tissue from healthy controls and schizophrenia cases (n = 58 total) was used to determine the localisation and abundance of IgG and IgG transporters and receptors in the midbrain of healthy controls and schizophrenia patients. Protein levels of IgG and FcGRT were quantified using western blot, and gene transcript levels of FcGRT, FcGR3A and FcGR2B were assessed using qPCR. The distribution of IgG in the midbrain was assessed using immunohistochemistry and immunofluorescence. Results were compared between diagnostic (schizophrenia vs control) and inflammatory (high vs low inflammation) groups. RESULTS We found that IgG and FcGRT protein abundance (relative to β-actin) was unchanged in people with schizophrenia compared with controls irrespective of inflammatory subtype. In contrast, FcGRT and FcGR3A mRNA levels were elevated in the midbrain from "high inflammation" schizophrenia cases (FcGRT; p = 0.02, FcGR3A; p < 0.0001) in comparison to low-inflammation patients and healthy controls, while FcGR2B mRNA levels were unchanged. IgG immunoreactivity was evident in the midbrain, and approximately 24% of all individuals (control subjects and schizophrenia cases) showed diffusion of IgG from blood vessels into the brain. However, the intensity and distribution of IgG was comparable across schizophrenia cases and control subjects. CONCLUSION These findings suggest that an increase in the pro-inflammatory Fcγ receptor FcGR3A, rather than an overall increase in IgG levels, contribute to midbrain neuroinflammation in schizophrenia patients. However, more precise information about IgG-Fcγ receptor interactions is needed to determine their potential role in schizophrenia neuropathology.
Collapse
Affiliation(s)
- A Petty
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
- School of Psychiatry, University of New South Wales, Sydney, NSW, 2052, Australia
| | - L J Glass
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
- Centre for Immunology and Allergy Research, Westmead Institute of Medical Research, The University of Sydney, Sydney, Australia
| | - D A Rothmond
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
| | - T Purves-Tyson
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia
- School of Psychiatry, University of New South Wales, Sydney, NSW, 2052, Australia
| | - A Sweeney
- NSW Brain Tissue Resource Centre, University of Sydney, Sydney, NSW, 2006, Australia
| | - Y Kondo
- Astellas Research Institute of America LLC, San Diego, CA, 92121, USA
| | - S Kubo
- Astellas Pharma Inc., Tsukuba, Ibaraki, 305-8585, Japan
| | - M Matsumoto
- Astellas Research Institute of America LLC, San Diego, CA, 92121, USA
| | - C Shannon Weickert
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Sydney, NSW, 2031, Australia.
- School of Psychiatry, University of New South Wales, Sydney, NSW, 2052, Australia.
- Department of Neuroscience and Physiology, Upstate Medical University, Syracuse, NY, 13210, USA.
| |
Collapse
|
9
|
Tanaka S, Iida H, Ueno M, Hirokawa F, Yoshida H, Ishii H, Nomi T, Nakai T, Kaibori M, Ikoma H, Noda T, Shinkawa H, Maehira H, Hayami S, Komeda K, Kubo S. Postoperative loss of independence 1 year after liver resection: prospective multicentre study. Br J Surg 2022; 109:e54-e55. [PMID: 35041737 DOI: 10.1093/bjs/znab452] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 12/08/2021] [Indexed: 11/14/2022]
Affiliation(s)
- S Tanaka
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - H Iida
- Division of Gastrointestinal, Breast, and General Surgery, Department of Surgery, Shiga University of Medical Science, Otsu, Japan
| | - M Ueno
- Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
| | - F Hirokawa
- Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Osaka, Japan
| | - H Yoshida
- Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - H Ishii
- Department of Medical Statistics, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - T Nomi
- Department of Surgery, Nara Medical University, Kashihara, Nara, Japan
| | - T Nakai
- Department of Surgery, Faculty of Medicine, Kindai University, Osaka-Sayama, Osaka, Japan
| | - M Kaibori
- Department of Surgery, Hirakata Hospital, Kansai Medical University, Hirakata, Osaka, Japan
| | - H Ikoma
- Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - T Noda
- Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan
| | - H Shinkawa
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - H Maehira
- Division of Gastrointestinal, Breast, and General Surgery, Department of Surgery, Shiga University of Medical Science, Otsu, Japan
| | - S Hayami
- Second Department of Surgery, Wakayama Medical University, Wakayama, Japan
| | - K Komeda
- Department of General and Gastroenterological Surgery, Osaka Medical College, Takatsuki, Osaka, Japan
| | - S Kubo
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
| |
Collapse
|
10
|
Warmer F, Tanaka K, Xanthopoulos P, Nunami M, Nakata M, Beidler CD, Bozhenkov SA, Beurskens MNA, Brunner KJ, Ford OP, Fuchert G, Funaba H, Geiger J, Gradic D, Ida K, Igami H, Kubo S, Langenberg A, Laqua HP, Lazerson S, Morisaki T, Osakabe M, Pablant N, Pasch E, Peterson B, Satake S, Seki R, Shimozuma T, Smith HM, Stange T, Stechow AV, Sugama H, Suzuki Y, Takahashi H, Tokuzawa T, Tsujimura T, Turkin Y, Wolf RC, Yamada I, Yanai R, Yasuhara R, Yokoyama M, Yoshimura Y, Yoshinuma M, Zhang D. Impact of Magnetic Field Configuration on Heat Transport in Stellarators and Heliotrons. Phys Rev Lett 2021; 127:225001. [PMID: 34889640 DOI: 10.1103/physrevlett.127.225001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 07/30/2021] [Accepted: 09/20/2021] [Indexed: 06/13/2023]
Abstract
We assess the magnetic field configuration in modern fusion devices by comparing experiments with the same heating power, between a stellarator and a heliotron. The key role of turbulence is evident in the optimized stellarator, while neoclassical processes largely determine the transport in the heliotron device. Gyrokinetic simulations elucidate the underlying mechanisms promoting stronger ion scale turbulence in the stellarator. Similar plasma performances in these experiments suggests that neoclassical and turbulent transport should both be optimized in next step reactor designs.
Collapse
Affiliation(s)
- Felix Warmer
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - K Tanaka
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- Kyushu University, Interdisciplinary Graduate School of Engineering Sciences, Plasma and Quantum Science and Engineering, Kasuga, Fukuoka 816-8580, Japan
| | - P Xanthopoulos
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - M Nunami
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
- Nagoya University, Graduate School of Science, Nagoya 464-8603, Japan
| | - M Nakata
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - C D Beidler
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - S A Bozhenkov
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - M N A Beurskens
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - K J Brunner
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - O P Ford
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - G Fuchert
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - H Funaba
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - J Geiger
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - D Gradic
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - K Ida
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - H Igami
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - S Kubo
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- Nagoya University, Graduate School of Science, Nagoya 464-8603, Japan
| | - A Langenberg
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - H P Laqua
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - S Lazerson
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - T Morisaki
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - M Osakabe
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - N Pablant
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - E Pasch
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - B Peterson
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - S Satake
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - R Seki
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - T Shimozuma
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - H M Smith
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - T Stange
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - A V Stechow
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - H Sugama
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - Y Suzuki
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - H Takahashi
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - T Tokuzawa
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - T Tsujimura
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - Y Turkin
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - R C Wolf
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| | - I Yamada
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - R Yanai
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - R Yasuhara
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - M Yokoyama
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - Y Yoshimura
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
| | - M Yoshinuma
- National Institute for Fusion Science, National Institutes on Natural Sciences, Toki, 509-5292, Japan
- SOKENDAI (The Graduate University for Advanced Studies), Toki, Gifu 509-5292, Japan
| | - D Zhang
- Max-Planck-Institut für Plasmaphysik, Wendelsteinstrasse 1, 17491 Greifswald, Germany
| |
Collapse
|
11
|
Takayama T, Yamazaki S, Matsuyama Y, Midorikawa Y, Shiina S, Izumi N, Hasegawa K, Kokudo N, Sakamoto M, Kubo S, Kudo M, Murakami T, Nakashima O. Prognostic grade for resecting hepatocellular carcinoma: multicentre retrospective study. Br J Surg 2021; 108:412-418. [PMID: 33793713 DOI: 10.1093/bjs/znaa109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2020] [Revised: 03/31/2020] [Accepted: 11/03/2020] [Indexed: 12/18/2022]
Abstract
BACKGROUND Surgical treatment for hepatocellular carcinoma (HCC) is advancing, but a robust prediction model for survival after resection is not available. The aim of this study was to propose a prognostic grading system for resection of HCC. METHODS This was a retrospective, multicentre study of patients who underwent first resection of HCC with curative intent between 2000 and 2007. Patients were divided randomly by a cross-validation method into training and validation sets. Prognostic factors were identified using a Cox proportional hazards model. The predictive model was built by decision-tree analysis to define the resection grades, and subsequently validated. RESULTS A total of 16 931 patients from 795 hospitals were included. In the training set (8465 patients), four surgical grades were classified based on prognosis: grade A1 (1236 patients, 14.6 per cent; single tumour 3 cm or smaller and anatomical R0 resection); grade A2 (3614, 42.7 per cent; single tumour larger than 3 cm, or non-anatomical R0 resection); grade B (2277, 26.9 per cent; multiple tumours, or vascular invasion, and R0 resection); and grade C (1338, 15.8 per cent; multiple tumours with vascular invasion and R0 resection, or R1 resection). Five-year survival rates were 73.9 per cent (hazard ratio (HR) 1.00), 64.7 per cent (HR 1.51, 95 per cent c.i. 1.29 to 1.78), 50.6 per cent (HR 2.53, 2.15 to 2.98), and 34.8 per cent (HR 4.60, 3.90 to 5.42) for grades A1, A2, B, and C respectively. In the validation set (8466 patients), the grades had equivalent reproducibility for both overall and recurrence-free survival (all P < 0.001). CONCLUSION This grade is used to predict prognosis of patients undergoing resection of HCC.
Collapse
Affiliation(s)
- T Takayama
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
| | - S Yamazaki
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
| | - Y Matsuyama
- Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan
| | - Y Midorikawa
- Department of Digestive Surgery, Nihon University School of Medicine, Tokyo, Japan
| | - S Shiina
- Department of Gastroenterology, Juntendo University School of Medicine, Tokyo, Japan
| | - N Izumi
- Department of Gastroenterology, Musashino Red Cross Hospital, Tokyo, Japan
| | - K Hasegawa
- Department of Hepato-biliary-pancreatic Surgery, School of Medicine, University of Tokyo, Tokyo, Japan
| | - N Kokudo
- Department of Hepato-biliary-pancreatic Surgery, National Center for Global Health and Medicine, Tokyo, Japan
| | - M Sakamoto
- Department of Pathology, Keio University School of Medicine, Tokyo, Japan
| | - S Kubo
- Department of Hepato-biliary-pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Kudo
- Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan
| | - T Murakami
- Department of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - O Nakashima
- Department of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Japan
| | | |
Collapse
|
12
|
Tokuzawa T, Tanaka K, Tsujimura T, Kubo S, Emoto M, Inagaki S, Ida K, Yoshinuma M, Watanabe KY, Tsuchiya H, Ejiri A, Saito T, Yamamoto K. W-band millimeter-wave back-scattering system for high wavenumber turbulence measurements in LHD. Rev Sci Instrum 2021; 92:043536. [PMID: 34243406 DOI: 10.1063/5.0043474] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 04/01/2021] [Indexed: 06/13/2023]
Abstract
A 90 GHz W-band millimeter-wave back-scattering system is designed and installed for measuring electron scale turbulence (k⊥ρs ∼ 40). A metal lens relay antenna is used for in-vessel beam focusing, and a beam diameter of less than 40 mm is achieved in the plasma core region. This antenna can be steered at an angle of 159° ± 6°, which almost covers the plasma radius. The estimated size of the scattering volume is ∼105 mm at the edge and 135 mm at the core, respectively. A 60 m corrugated waveguide is used to achieve a low transmission loss of ∼8 dB. A heterodyne detection system for millimeter-wave circuits with probing power modulation can distinguish the scattered signal from background noise.
Collapse
Affiliation(s)
- T Tokuzawa
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - K Tanaka
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - T Tsujimura
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - S Kubo
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - M Emoto
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - S Inagaki
- Research Institute for Applied Mechanics, Kyushu University, Kasuga 816-8580, Japan
| | - K Ida
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - M Yoshinuma
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - K Y Watanabe
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - H Tsuchiya
- National Institutes of Natural Sciences, National Institute for Fusion Science, Toki 509-5292, Japan
| | - A Ejiri
- Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa 277-8561, Japan
| | - T Saito
- Research Center for Development of Far-Infrared Region, University of Fukui, Bunkyo 3-9-1, Fukui 910-8507, Japan
| | - K Yamamoto
- Research Center for Development of Far-Infrared Region, University of Fukui, Bunkyo 3-9-1, Fukui 910-8507, Japan
| |
Collapse
|
13
|
Troisi RI, Berardi G, Morise Z, Cipriani F, Ariizumi S, Sposito C, Panetta V, Simonelli I, Kim S, Goh BKP, Kubo S, Tanaka S, Takeda Y, Ettorre GM, Russolillo N, Wilson GC, Cimino M, Montalti R, Giglio MC, Igarashi K, Chan CY, Torzilli G, Cheung TT, Mazzaferro V, Kaneko H, Ferrero A, Geller DA, Han HS, Kanazawa A, Wakabayashi G, Aldrighetti L, Yamamoto M. Laparoscopic and open liver resection for hepatocellular carcinoma with Child-Pugh B cirrhosis: multicentre propensity score-matched study. Br J Surg 2021; 108:196-204. [PMID: 33711132 DOI: 10.1093/bjs/znaa041] [Citation(s) in RCA: 71] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2020] [Revised: 06/03/2020] [Accepted: 09/18/2020] [Indexed: 02/06/2023]
Abstract
BACKGROUND Laparoscopic liver resection for hepatocellular carcinoma (HCC) in Child-Pugh A cirrhosis has been demonstrated as beneficial. However, the role of laparoscopy in Child-Pugh B cirrhosis is undetermined. The aim of this retrospective cohort study was to compare open and laparoscopic resection for HCC with Child-Pugh B cirrhosis. METHODS Data on liver resections were gathered from 17 centres. A 1 : 1 propensity score matching was performed according to 17 predefined variables. RESULTS Of 382 available liver resections, 100 laparoscopic and 100 open resections were matched and analysed. The 90-day postoperative mortality rate was similar in open and laparoscopic groups (4.0 versus 2.0 per cent respectively; P = 0.687). Laparoscopy was associated with lower blood loss (median 110 ml versus 400 ml in the open group; P = 0.004), less morbidity (38.0 versus 51.0 per cent respectively; P = 0.041) and fewer major complications (7.0 versus 21.0 per cent; P = 0.010), and ascites was lower on postoperative days 1, 3 and 5. For laparoscopic resections, patients with portal hypertension developed more complications than those without (26 versus 12 per cent respectively; P = 0.002), and patients with a Child-Pugh B9 score had higher morbidity rates than those with B8 and B7 (7 of 8, 10 of 16 and 21 of 76 respectively; P < 0.001). Median hospital stay was 7.5 (range 2-243) days for laparoscopic liver resection and 18 (3-104) days for the open approach (P = 0.058). The 5-year overall survival rate was 47 per cent for open and 65 per cent for laparoscopic resection (P = 0.142). The 5-year disease-free survival rate was 32 and 37 per cent respectively (P = 0.742). CONCLUSION Patients without preoperative portal hypertension and Child-Pugh B7 cirrhosis may benefit most from laparoscopic liver surgery.
Collapse
Affiliation(s)
- R I Troisi
- Division of HPB, Minimally Invasive and Robotic Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.,Department of Human Structure and Repair, Ghent University, Ghent, Belgium
| | - G Berardi
- Division of HPB, Minimally Invasive and Robotic Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.,Department of Human Structure and Repair, Ghent University, Ghent, Belgium.,Centre for Advanced Treatment of Hepato-Biliary-Pancreatic Diseases, Ageo Central General Hospital, Tokyo, Japan
| | - Z Morise
- Department of Surgery, Fujita Health University Hospital, Toyoake, Japan
| | - F Cipriani
- Hepatobiliary Surgery Division, San Raffaele Hospital, Milan, Italy
| | - S Ariizumi
- Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
| | - C Sposito
- Department of Hepato-Biliary-Pancreatic Surgery and Liver Transplantation, Istituto Nazionale Tumori, Milan, Italy
| | - V Panetta
- Biostatistics Department, Sapienza University of Rome, Rome, Italy
| | - I Simonelli
- Biostatistics Department, Sapienza University of Rome, Rome, Italy
| | - S Kim
- Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul,South Korea
| | - B K P Goh
- Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore
| | - S Kubo
- Department of Surgery, Osaka City University Hospital, Osaka, Japan
| | - S Tanaka
- Department of Surgery, Osaka City University Hospital, Osaka, Japan
| | - Y Takeda
- Department of Surgery, Kansai Rosai Hospital, Amagasaki, Japan
| | - G M Ettorre
- Department of General and Hepato-Biliary-Pancreatic Surgery, Liver Transplantation Service, San Camillo Forlanini Hospital, Rome, Italy
| | - N Russolillo
- Department of Surgery, Mauriziano Hospital, Turin, Italy
| | - G C Wilson
- Division of Hepatobiliary and Pancreatic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - M Cimino
- Department of General Surgery, Humanitas University and Research Hospital, IRCCS, Milan, Italy
| | - R Montalti
- Department of Public Health, Federico II University, Naples, Italy
| | - M C Giglio
- Division of HPB, Minimally Invasive and Robotic Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy
| | - K Igarashi
- Centre for Advanced Treatment of Hepato-Biliary-Pancreatic Diseases, Ageo Central General Hospital, Tokyo, Japan
| | - C-Y Chan
- Department of Hepatopancreatobiliary and Transplant Surgery, Singapore General Hospital, Singapore
| | - G Torzilli
- Department of General Surgery, Humanitas University and Research Hospital, IRCCS, Milan, Italy
| | - T T Cheung
- Division of Hepato-Biliary-Pancreatic and Liver Transplantation, Queen Mary Hospital, University of Hong Kong, Hong Kong, China
| | - V Mazzaferro
- Department of Hepato-Biliary-Pancreatic Surgery and Liver Transplantation, Istituto Nazionale Tumori, Milan, Italy
| | - H Kaneko
- Department of Surgery, Toho University of Tokyo, Tokyo, Japan
| | - A Ferrero
- Department of Surgery, Mauriziano Hospital, Turin, Italy
| | - D A Geller
- Division of Hepatobiliary and Pancreatic Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
| | - H-S Han
- Department of Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seoul,South Korea
| | - A Kanazawa
- Department of Surgery, Osaka City General Hospital, Osaka, Japan
| | - G Wakabayashi
- Centre for Advanced Treatment of Hepato-Biliary-Pancreatic Diseases, Ageo Central General Hospital, Tokyo, Japan
| | - L Aldrighetti
- Hepatobiliary Surgery Division, San Raffaele Hospital, Milan, Italy
| | - M Yamamoto
- Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
| |
Collapse
|
14
|
Nishiura M, Shimizu T, Kobayashi S, Tokuzawa T, Ichinose K, Kubo S. Q-band high-performance notch filters at 56 and 77 GHz notches for versatile fusion plasma diagnostics. Rev Sci Instrum 2021; 92:034711. [PMID: 33820101 DOI: 10.1063/5.0041243] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Accepted: 02/24/2021] [Indexed: 06/12/2023]
Abstract
A six-pole Q-band waveguide filter with a notch frequency above the Q-band has been developed for plasma diagnostics. The previous paper [Nishiura et al., J. Instrum. 10, C12014 (2015)] reported that the notch frequency exists within the standard band. In this study, the newly required notch filter extends the function, which prevents a thorny wave from being mixed into an instrument beyond the standard bandwidth of the waveguide. The mode control technique for cavities realizes a deep and sharp filter shape for Q-band notch filters with 56 and 77 GHz notches, respectively. The former filter has an attenuation more than 50 dB at 56.05 GHz and a bandwidth of 1.1 GHz at -3 dB. The latter filter has an attenuation more than 55 dB at 76.95 GHz and a bandwidth of 1.6 GHz at -3 dB. The electron cyclotron emission imaging and the electron cyclotron emission (ECE) diagnostics for the Q-band implemented a pair of the fabricated filters and demonstrated the ECE measurement successfully in the intense stray radiation from a 56 GHz gyrotron.
Collapse
Affiliation(s)
- M Nishiura
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - T Shimizu
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - S Kobayashi
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - T Tokuzawa
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| | - K Ichinose
- Graduate School of Engineering, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan
| | - S Kubo
- National Institute for Fusion Science, 322-6 Oroshi-cho, Toki, Gifu 509-5292, Japan
| |
Collapse
|
15
|
Masumoto A, Ohya M, Murai R, Miura K, Shimada T, Amano H, Kubo S, Tada T, Tanaka H, Fuku Y, Kadota K. Early restenosis and late catch-up phenomenon after newer biodegradable- and durable-polymer drug-eluting stent implantations. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
It is yet to be known whether mechanisms underlying restenosis in newer-generation durable-polymer (DP) and biodegradable-polymer (BP) drug-eluting stents (DES) are different.
Purpose
This study aims to assess the incidences and predictors of early restenosis and late catch-up phenomenon after newer-generation durable-polymer (DP) and biodegradable-polymer (BP) DES.
Methods
Between 2010 and 2017, 13858 lesions in 6350 patients were treated with DES (4393 BP-DES, 9465 DP-DES). The early-term (within 1 year) and late-term (from 1 to 2 years) follow-up angiographies were scheduled. Late catch-up phenomenon was defined as in-stent restenosis (ISR) in lesions that evaded ISR within 1 year after stent implantation. ISR was defined as angiographic restenosis of more than 50%.
Results
The mean patient age was 71 years, and 76.7% were male. Early-term angiographies were performed in 10955 lesions (79.0%). Of those without early-term ISR, late-term angiographies were performed in 7771 lesions (56.1%). The incidences of mid-term restenosis and late catch-up phenomenon were 6.6% and 3.9%, respectively.
In the multivariate regression analyses, history of diabetes, hemodialysis and previous PCI were independent predictors of both early restenosis and late catch-up phenomenon. Also, some lesion characteristics such as chronic total occlusion, right coronary artery ostial lesion, small vessel (defined as reference diameter <2.5mm), long lesion (defined as lesion length >30mm) and treatment of ISR lesion were independent predictors of both early restenosis and late catch-up phenomenon.
Bifurcation lesion and heavily calcified lesion treated with rotablator were independent risk of early restenosis. Bypass graft lesion was an independent predictor of late catch-up phenomenon.
Early restenosis was observed less frequently in DP-DES than in BP-DES (6.3% versus 7.4%, P=0.012). On the contrary, late catch-up phenomenon was observed more frequently in DP-DES than in BP-DES (4.3% versus 2.9%, P=0.026).
Conclusions
Some lesion characteristics were independent predictors of early restenosis and late catch-up phenomenon after newer-generation DES implantation. The deployment of BP-DES resulted in more early restenosis and less late catch-up phenomenon compared to that of DP-DES.
Early Restenosis and Late Catch-Up
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
| | - M Ohya
- Kurashiki Central Hospital, Kobe, Japan
| | - R Murai
- Kurashiki Central Hospital, Kobe, Japan
| | - K Miura
- Kurashiki Central Hospital, Kobe, Japan
| | - T Shimada
- Kurashiki Central Hospital, Kobe, Japan
| | - H Amano
- Kurashiki Central Hospital, Kobe, Japan
| | - S Kubo
- Kurashiki Central Hospital, Kobe, Japan
| | - T Tada
- Kurashiki Central Hospital, Kobe, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Kobe, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Kobe, Japan
| | - K Kadota
- Kurashiki Central Hospital, Kobe, Japan
| |
Collapse
|
16
|
Hata R, Shimada T, Shima Y, Okabe K, Ohya M, Miura K, Murai R, Amano H, Kubo S, Tada T, Tanaka H, Fuku Y, Goto T, Kadota K. Clinical features and prognosis of acute myocardial infarction due to coronary artery embolism. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Coronary artery embolism (CE) is one of the important causes of acute coronary syndrome (ACS). The feature of CE is that angiographic evidence of coronary artery embolism and thrombosis without atherosclerotic components. However, the prevalence of CE remains unknown because of the diffifulty to diagnose in the acute settings. A recent retrospective analysis suggested that up to 3% of ACS cases may result from CE.
Purpose
The aim of this study was to elucidate the prevalence, clinical features and long-term outcomes including all-cause and cardiac death.
Methods
We analysed the consecutive 2695 patients with first AMI performed coronary intervention between January 2004 and July 2017. CE was diagnosed by clinical histories and angiographic findings. We retrospectively evaluated the clinical and lesion characteristics and outcomes including all-cause and cardiac death.
Results
The prevalence of CE was 2.0% (n=55; CE group and n=2640; non-CE group), including 8 (15%) patients with multivessel CE. The CE group had higher average age (70.8±14.9 vs. 68.4±12.6, p<0.01), prevalence of female (54% vs. 27%, p<0.01), lower prevalence of smoking (34% vs. 62%, p<0.01). The common causes with CE were atrial fibrillation (47%), and malignant tumor (9%), and cardiomyopathy (5%), and patent foramen ovale (4%). Only 20% of patients with CE were treated with anti-coagulant therapy. The rate of distal infarction site (defined as #4, #8, #14–15) was significantly higher in CE group than non-CE group (54.0% vs. 4.9%, p<0.01). During median follow-up of 53.6 [32.6–77.3] months, CE and thromboembolism recurred in 5 patients (CE: 1 patient, stroke 4 patients). The 4-year incidence of all-cause death was significantly higher in the CE group, but cardiac death was not significantly different between the groups (28.8% vs. 14.8%, p=0.03; 12.8% vs. 5.1%, p=0.11).
Conclusion
Compared with non-CE group, the prevalence of distal infarction site was significantly higher in the CE group, and the incidence of cardiac death is not significantly different.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- R Hata
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - Y Shima
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - K Okabe
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - M Ohya
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - K Miura
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - R Murai
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - H Amano
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Cardiology, Kurashiki, Japan
| |
Collapse
|
17
|
Miura K, Shimada T, Ohya M, Murai R, Amano H, Kubo S, Tada T, Tanaka H, Fuku Y, Goto T, Kadota K. Risk stratification based on academic research consortium high bleeding risk criteria for long-term bleeding event after everolimus-eluting stent implantation. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Recently, the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria has been suggested as the standard definition of HBR.
Purpose
We aimed to investigate the risk stratification based on ARC-HBR Criteria for long-term bleeding event after everolimus-eluting stent implantation
Methods
The study population comprised 1193 patients treated with EES without in-hospital event between 2010 and 2011. Individual ARC-HBR criteria was retrospectively assessed. Major bleeding were defined as the occurrence of a Bleeding Academic Research Consortium type 3 or 5 bleeding event. The mean follow-up period was 2996±433 days.
Results
There were 656 patients (55.0%) in HBR-groups. Cumulative incidence of major bleeding was significantly higher in HBR-group (8.1% vs 3.4% at 4 year, and 16.2% vs 5.7% at 8 year, P<0.001). Cumulative rate of major bleeding tend to be higher as the number of ARC-HBR criteria increased (≥2 Majors: 24.3%, 1 Major: 17.0%, ≥2 Minors:11.7%, and Non-HBR: 5.7%, P<0.001).
Conclusion
ARC-HBR criteria successfully stratified the long-term bleeding risk after drug-eluting stent implantation in real-world practice.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Miura
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Kurashiki, Japan
| | - M Ohya
- Kurashiki Central Hospital, Kurashiki, Japan
| | - R Murai
- Kurashiki Central Hospital, Kurashiki, Japan
| | - H Amano
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Kurashiki, Japan
| |
Collapse
|
18
|
Aoki T, Kubota K, Kubo S, Kudo M. Author response to: Comment on: Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. Br J Surg 2020; 107:470. [PMID: 32129488 DOI: 10.1002/bjs.11522] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Accepted: 01/09/2020] [Indexed: 12/17/2022]
Affiliation(s)
- T Aoki
- Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan
| | - K Kubota
- Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan
| | - S Kubo
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine and, Osaka, Japan
| | - M Kudo
- Department of Gastroenterology and Hepatology, Kindai University School of Medicine, Osaka, Japan
| |
Collapse
|
19
|
Miyazaki Y, Nakano K, Nakayamada S, Kubo S, Iwata S, Hanami K, Fukuyo S, Miyagawa I, Yamaguchi A, Kawabe A, Kazuyoshi S, Tanaka Y. FRI0102 SERUM TNFΑ LEVELS AT 24 HOURS AFTER FIRST ADMINISTRATION OF CERTOLIZUMAB PEGOL PREDICT EFFECTIVENESS AT WEEK 12 IN PATIENTS WITH RHEUMATOID ARTHRITIS FROM TSUBAME STUDY (UMIN ID:0002381). Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:To increase the remission rate of rheumatoid arthritis (RA), it is necessary to determine the efficacy of the tumor necrosis factor (TNF) inhibitor as early as possible. Moreover, the response to certolizumab pegol (CZP) at 12 weeks has been reported to predict its long-term efficacy.Objectives:As part of a prospective single-center observational study (TSUBAME study), we prospectively enrolled patients to be treated with CZP in our institution to evaluate its effectiveness and safety starting at 24 hours after the first dose in clinical settings, while recording blood CZP concentrations and biomarkers over time to examine their correlation with clinical effects.Methods:One hundred patients with RA and inadequate response to MTX who received CZP were enrolled in the TSUBAME study. The changes in serum TNFα, IL-6, and CZP levels at 24 hours after first administration of CZP were measured, and the correlation between serum biomarkers and clinical response was determined.Results:At 24 hours after CZP initiation, significant improvement was observed in the disease activity (baseline and 24 h: 5.4 ± 1.3, 5.0 ± 1.3, respectively, p < 0.01), which was maintained until week 12. (baseline and 12 w: 5.4 ± 1.3, 3.3 ± 1.4, respectively, p < 0.01). Serum TNFα and IL-6 levels significantly decreased at 24 hours after first administration of CZP compared to baseline. No correlation was found between TNFα and IL-6 levels at baseline and the clinical response. According to univariate analysis, low serum TNFα and IL-6 levels and high CZP levels at 24 hours were associated with DAS28 (ESR) remission at 12 weeks. According to multivariate analysis, low serum TNFα levels at 24 hours were significantly associated with DAS28 (ESR) remission at 12 weeks (OR 0.05, 95%CI 0.01, 0.75, p = 0.03). Based on these findings, an ROC curve was created using remission according to the DAS28 (ESR) at week 12 as a dependent variable and TNFα concentration at 24 hours as an independent variable, resulting in a cut-off value of 0.76 pg/ml. From this result, the TNFα concentration at 24 hours was divided into 2 groups according to this cut-off, and the rates of remission according to the DAS28 (ESR) at week 12 were compared. In the group with TNFα concentration at 24 hours below the cut-off value, the rate of remission according to the DAS28 (ESR) at week 12 was significantly higher than in the group with TNFα concentration at 24 hours above the cut-off value (below the cut-off: above the cut-off = 56.3%: 21.6%, p < 0.001). Between the group that achieved remission according to the DAS28(ESR) and the group that did not achieve remission at week 12, there was almost no difference in the distribution of TNFα concentrations at baseline; however, the distribution of TNFα concentrations at 24 hours was lower in the group that achieved remission.Conclusion:CZP was effective where serum TNFα was strongly neutralized within 24 hours. These results suggest that low serum TNFα levels at 24 hours after first administration of CZP may predict the effectiveness of CZP. To increase the remission rate in RA, it is necessary to determine the effectiveness of the molecular targeted drugs used at an early point, in addition to how rapid the onset of action is. CZP is extremely fast-acting, and its effectiveness can be predicted as early as 24 hours after the first dose, suggesting that it may be possible to determine the effectiveness early.Acknowledgments:The authors thank Ms. M. Hirahara for providing excellent technical assistance.Disclosure of Interests:Yusuke Miyazaki Grant/research support from: Astellas Pharma Inc and UCB S.A., Kazuhisa Nakano: None declared, Shingo Nakayamada Grant/research support from: Mitsubishi-Tanabe, Takeda, Novartis and MSD, Speakers bureau: Bristol-Myers, Sanofi, Abbvie, Eisai, Eli Lilly, Chugai, Asahi-kasei and Pfizer, Satoshi Kubo: None declared, Shigeru Iwata: None declared, Kentaro Hanami: None declared, Shunsuke Fukuyo: None declared, Ippei Miyagawa: None declared, Ayako Yamaguchi: None declared, Akio Kawabe: None declared, SAITO KAZUYOSHI: None declared, Yoshiya Tanaka Grant/research support from: Asahi-kasei, Astellas, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers, UCB, Daiichi-Sankyo, Eisai, Pfizer, and Ono, Consultant of: Abbvie, Astellas, Bristol-Myers Squibb, Eli Lilly, Pfizer, Speakers bureau: Daiichi-Sankyo, Astellas, Chugai, Eli Lilly, Pfizer, AbbVie, YL Biologics, Bristol-Myers, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Sanofi, UCB, and Teijin
Collapse
|
20
|
Ii Tsujimura T, Mizuno Y, Yanai R, Tokuzawa T, Ito Y, Nishiura M, Kubo S, Shimozuma T, Yoshimura Y, Igami H, Takahashi H, Tanaka K, Yoshinuma M, Ohshima S. Real-time control of the deposition location of ECRH in the LHD. Fusion Engineering and Design 2020. [DOI: 10.1016/j.fusengdes.2020.111480] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Aoki T, Kubota K, Kubo S, Kudo M. Author response to: Comment on: Significance of the surgical hepatic resection margin in patients with a single hepatocellular carcinoma. Br J Surg 2020; 107:465. [PMID: 32129493 DOI: 10.1002/bjs.11495] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Accepted: 12/06/2019] [Indexed: 11/09/2022]
Affiliation(s)
- T Aoki
- Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan
| | - K Kubota
- Second Department of Surgery, Dokkyo Medical University, Tochigi, Japan
| | - S Kubo
- Department of Hepato-Biliary-Pancreatic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan
| | - M Kudo
- Department of Gastroenterology and Hepatology, Kindai University School of Medicine, Osaka, Japan
| |
Collapse
|
22
|
Motoki N, Mizuki M, Tsukahara T, Miyakawa M, Kubo S, Oda H, Tanaka M, Yamauchi K, Abe F, Nomiyama T. Effects of Lactoferrin-Fortified Formula on Acute Gastrointestinal Symptoms in Children Aged 12-32 Months: A Randomized, Double-Blind, Placebo-Controlled Trial. Front Pediatr 2020; 8:233. [PMID: 32509712 PMCID: PMC7249745 DOI: 10.3389/fped.2020.00233] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Accepted: 04/17/2020] [Indexed: 12/21/2022] Open
Abstract
Objective: We investigated the effects of lactoferrin (LF)-fortified formula on acute gastrointestinal and respiratory symptoms in children. Design: Randomized, double-blind, placebo-controlled trial. Setting and subjects: Children aged 12-32 months in Japan. Intervention: Intake of placebo or LF (48 mg/day)-fortified formula for 13 weeks. Primary endpoint: Prevalence of acute gastrointestinal and respiratory symptom. Results: One hundred nine participants were randomized. Eight participants were lost to follow-up, withdrew consent, or were deemed inappropriate for the trial, with 101 participants receiving complete analyses (placebo group, n = 48; LF group, n = 53). Outcomes: The prevalence of acute gastrointestinal symptoms was significantly less in the LF group (22/53 [41.5%]) than in the placebo group (30/48 [62.5%], p = 0.046). The total number of days having acute respiratory symptoms was significantly lower in the LF group (9.0) than in the placebo group (15.0, p = 0.030). Harms: The rate of adverse events was similar between the groups. No adverse drug reactions were found. Conclusions: LF intake decreased the prevalence of acute gastrointestinal symptoms in children aged 12-32 months.
Collapse
Affiliation(s)
- Noriko Motoki
- Department of Preventive Medicine and Public Health, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| | - Masaru Mizuki
- Department of Preventive Medicine and Public Health, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| | - Teruomi Tsukahara
- Department of Preventive Medicine and Public Health, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| | - Momoko Miyakawa
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry, Co., Ltd., Zama, Kanagawa, Japan
| | - Shutaro Kubo
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry, Co., Ltd., Zama, Kanagawa, Japan
| | - Hirotsugu Oda
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry, Co., Ltd., Zama, Kanagawa, Japan
| | - Miyuki Tanaka
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry, Co., Ltd., Zama, Kanagawa, Japan
| | - Koji Yamauchi
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry, Co., Ltd., Zama, Kanagawa, Japan
| | - Fumiaki Abe
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry, Co., Ltd., Zama, Kanagawa, Japan
| | - Tetsuo Nomiyama
- Department of Preventive Medicine and Public Health, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| |
Collapse
|
23
|
Miyakawa M, Kubo S, Oda H, Motoki N, Mizuki M, Tsukahara T, Tanaka M, Yamauchi K, Abe F, Nomiyama T. Effects of Lactoferrin on Sleep Conditions in Children Aged 12-32 Months: A Preliminary, Randomized, Double-Blind, Placebo-Controlled Trial. Nat Sci Sleep 2020; 12:671-677. [PMID: 33061724 PMCID: PMC7532897 DOI: 10.2147/nss.s263106] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2020] [Accepted: 08/19/2020] [Indexed: 01/10/2023] Open
Abstract
PURPOSE To investigate preliminarily the effect of lactoferrin (LF)-fortified formula on sleep conditions in children. STUDY DESIGN A preliminary, randomized, double-blind, placebo-controlled trial. METHODS Healthy children between the ages of 12 and 32 months who attended nursery schools in Japan were divided into two groups and assigned a placebo or LF (48 mg/day)-fortified formula. Children's sleep conditions were investigated before and after the 13-week intervention using the Japanese Sleep Questionnaire for Preschoolers (JSQ-P). RESULTS Altogether, 109 participants were randomized. Eight participants were eliminated due to lost to follow-up, withdrawal of consent, and ineligibility, with 101 participants (placebo, n = 48; LF, n = 53) included in the full analysis set (FAS) and used for analysis. Wake-up time, bedtime, and nighttime sleep were comparable between the two groups before and after intervention. The change in total JSQ-P T scores tended to improve in the LF group (placebo vs LF: 0.5 ± 6.5 vs -1.9 ± 6.1, p = 0.074), in particular, morning symptoms significantly improved (grumpy in the morning, hard to wake-up, and hard to get out of bed) (placebo vs LF: 0.8 ± 6.2 vs -1.9 ± 6.2, p = 0.028). A better trend was also observed in the LF group regarding restless legs syndrome (RLS)-motor (rubs feet at night and touches feet at night) (placebo vs LF: 2.3 ± 10.7 vs -0.6 ± 13.5, p = 0.083) and insufficient sleep (stays up more than one hour later the day before a holiday and wakes up more than one hour later on a holiday) (placebo vs LF: 0.1 ± 9.8 vs -1.7 ± 8.8, p = 0.095). No adverse drug reactions were found. CONCLUSION LF intake may improve sleep condition, especially morning symptoms in children above one year of age.
Collapse
Affiliation(s)
- Momoko Miyakawa
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd, Zama, Kanagawa, Japan
| | - Shutaro Kubo
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd, Zama, Kanagawa, Japan
| | - Hirotsugu Oda
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd, Zama, Kanagawa, Japan
| | - Noriko Motoki
- Department of Preventive Medicine and Public Health, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| | - Masaru Mizuki
- Department of Preventive Medicine and Public Health, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| | - Teruomi Tsukahara
- Department of Preventive Medicine and Public Health, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| | - Miyuki Tanaka
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd, Zama, Kanagawa, Japan
| | - Koji Yamauchi
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd, Zama, Kanagawa, Japan
| | - Fumiaki Abe
- Food Ingredients and Technology Institute, R&D Division, Morinaga Milk Industry Co., Ltd, Zama, Kanagawa, Japan
| | - Tetsuo Nomiyama
- Department of Preventive Medicine and Public Health, Shinshu University School of Medicine, Matsumoto, Nagano, Japan
| |
Collapse
|
24
|
Okabe K, Ohya M, Matsushita K, Kuwayama A, Murai R, Miura K, Shimada T, Amano H, Kubo S, Habara S, Tada T, Tanaka H, Fuku Y, Goto T, Kadota K. P2693Late catch-up phenomenon and late-term target lesion revascularization of two-stenting for coronary bifurcation lesions between first and second generation drug-eluting stents. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
The second generation drug-eluting stent (G2-DES) has been reported as superior to the first generation drug-eluting stent (G1-DES) in mid-term outcomes. However, the late-term outcomes between G1-DES and G2-DES in two-stenting for coronary bifurcation lesions are not well studied.
Purpose
To evaluate the late catch-up phenomenon and late-term target lesion revascularization (TLR) of two-stenting for coronary bifurcation lesions between G1-DES and G2-DES.
Methods
This study included 1133 lesions in 1089 patients undergoing drug eluting stent implantation with two stenting from 2004 to 2016. These consisted of 496 G1-DES implanted lesions and 637 G2-DES implanted lesions. Late-term follow-up angiography was performed without in-stent restenosis (ISR) and TLR at mid-term follow-up in 582 lesions (242 G1-DES lesions and 340 G2-DES lesions). ISR was defined as more than 50% restenosis. Late catch-up phenomenon was defined as ISR without ISR within 1 year following index stent implantation. Late-term TLR was defined as from 1 to 5 year TLR. Bifurcation lesions were defined as the main branch ranging from the proximal stem to the distal main branch with boundaries defined by 5 mm proximal and distal to the stent-implanted area, and the side branch ranging from the bifurcation carina to the distal side branch with boundaries defined by the carina and 5 mm distal to the stent-implanted area.
Results
The median follow-up duration was 5.1 years (the first and third quarters, 3.2 and 7.1 years). The late-catch up phenomenon rate significantly differed between the G1-DES and G2-DES groups (16.9% vs 8.4%, p=0.001). A significant difference in late catch-up between the same two groups was also observed in bifurcation lesions of the main branch (5.0% vs 0.6%, p=0.001) and side branch (10.3% vs 5.6%, p=0.033), respectively. The 5-year cumulative rates also differed between the two groups in TLR (8.2% vs 3.7% log-rank p=0.001), and late-term TLR (7.0% vs 3.6% log-rank p=0.001).
Conclusion
Two-stenting using G2-DES, compared with G1-DES, significantly reduced late-term restenosis and TLR. The restenosis rate in bifurcation area may be associated with differences between two groups in late-term outcome.
Collapse
Affiliation(s)
- K Okabe
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - M Ohya
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - K Matsushita
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - A Kuwayama
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - R Murai
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - K Miura
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - H Amano
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - S Habara
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Department of Cardiology, Kurashiki, Japan
| |
Collapse
|
25
|
Tada T, Miura K, Ohya M, Shimada T, Murai R, Amano H, Kubo S, Habara S, Tanaka H, Fuku Y, Kadota K. P5614The association between tissue morphology assessed with optical coherence tomography and mid and late-term results after percutaneous coronary intervention for in-stent restenosis lesions. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
It was reported that tissue morphology of in-stent restenosis (ISR) lesions assessed with optical coherence tomography (OCT) had an effect on midterm results including ISR and target lesion revascularization (TLR) rates after percutaneous coronary intervention (PCI). However, little was known about the association between tissue morphology assessed with OCT and late-term results.
Methods
We performed PCI treated with paclitaxel coated balloon (PCB) or drug-eluting stent (DES) for 452 ISR lesions (260 lesions with fibrous plaque and 192 lesions with lipid-laden plaque) using OCT between May 2008 and July 2016. Six- to eight-month (midterm) angiographic follow-up was performed on 422 of the 452 ISR lesions (follow-up rate: 93.4%). Furthermore, eighteen- to twenty-month (late-term) angiographic follow-up was performed on 337 of the 361 ISR lesions (follow-up rate: 93.4%) which were free from midterm TLR. We examined the association between tissue morphology, midterm-results and late-term results including ISR and TLR rates. Fibrous plaque was defined as homogeneous, signal-rich regions with low attenuation. Lipid-laden plaque was defined as diffuse border, signal poor regions with high attenuation.
Results
The patients were 353 men and 69 women, and the mean age was 68.8±9.6 years. PCI were performed with PCB in 285 lesions (PCB group) and DES in 137 lesions (DES group). The figure shows the angiographic midterm results of the 422 lesions and late-term results of the 337 lesions with respect to each tissue morphology and each PCI device. There was no difference in ISR and TLR rates of lesions with both fibrous and lipid-laden plaque at midterm between the two groups. ISR and TLR rates of lesions with lipid-laden plaque at late-term were significantly higher in the PCB group than in the DES group, while there was no difference in ISR and TLR rates of lesions with fibrous plaque at late-term between two groups.
Figure 1
Conclusion
Tissue morphology of ISR lesions might have an impact on outcomes after PCI. Morphological assessment of ISR tissue using OCT might suggest favorable types of PCI for ISR lesions.
Collapse
Affiliation(s)
- T Tada
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - K Miura
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - M Ohya
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - R Murai
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - H Amano
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - S Habara
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| |
Collapse
|
26
|
Idei H, Onchi T, Kariya T, Tsujimura T, Kubo S, Kobayashi S, Sakaguchi M, Imai T, Hasegawa M, Nakamura K, Mishra K, Fukuyama M, Yunoki M, Kojima S, Watanabe O, Kuroda K, Hanada K, Nagashima Y, Ejiri A, Matsumoto N, Ono M, Higashijima A, Nagata T, Shimabukoro S, Takase Y, Fukuyama A, Murakami S. 28-GHz ECHCD system with beam focusing launcher on the QUEST spherical tokamak. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.02.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
27
|
Fukuyama M, Idei H, Tsujimura T, Kubo S, Kobayashi S, Yunoki M, Onchi T, Ikezoe R. Quasi-optical polarizer system for ECHCD experiments in the QUEST. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.02.099] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
28
|
Nagasaki K, Watanabe S, Sakamoto K, Isayama A, Okada H, Minami T, Kado S, Kobayashi S, Yamamoto S, Ohshima S, Konoshima S, Mizuuchi T, Nakamura Y, Ishizawa A, Kubo S, Igami H, Weir G, Marushchenko N. Measurement of stray millimeter-wave radiation from a 70-GHz ECH/ECCD system in Heliotron J. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.04.051] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
29
|
Nishikawa T, Miyamatsu N, Higashiyama A, Hojo M, Nishida Y, Fukuda S, Ichiura K, Kubo S, Ueba T, Okamura T. Difference in water intake between persons with a history of cerebral infarction and healthy persons. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky214.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - N Miyamatsu
- Department of Clinical Nursing, Shiga University of Medical Science, Shiga, Japan
| | - A Higashiyama
- Department of Preventive Medicine and Epidemiologic Informatics, National Cerebral and Cardiovascular Center, Osaka, Japan
| | - M Hojo
- Department of Neurosurgery, Shiga General Hospital, Shiga, Shiga, Japan
| | - Y Nishida
- Foundation for Biomedical Research and Innovation, Hyogo, Japan
| | - S Fukuda
- Department of Neurosurgery, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
| | - K Ichiura
- Department of Clinical Nursing, Shiga University of Medical Science, Shiga, Japan
| | - S Kubo
- Foundation for Biomedical Research and Innovation, Hyogo, Japan
| | - T Ueba
- Department of Neurosurgery, Kochi Medical School, Kochi University, Kochi, Japan
| | - T Okamura
- Department of Preventive Medicine and Public Health, School of Medicine, Keio University, Tokyo, Japan
| |
Collapse
|
30
|
Nomura T, Maeno Y, Abramowitz Y, Yoon S, Kubo S, Jilaihawi H, Kawamori H, Kazuno Y, Miyasaka M, Takahashi N, Kashif M, Chakravarty T, Nakamura M, Sharma R, Makkar R. P6311Prognostic impact of permanent pacemaker implantation in patients with low left ventricular ejection fraction following transcatheter aortic valve replacement. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p6311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Nomura
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - Y Maeno
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - Y Abramowitz
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - S Yoon
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - S Kubo
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - H Jilaihawi
- New York University Langone Medical Center, New York, United States of America
| | - H Kawamori
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - Y Kazuno
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - M Miyasaka
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - N Takahashi
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - M Kashif
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - T Chakravarty
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - M Nakamura
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - R Sharma
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| | - R Makkar
- Cedars-Sinai Medical Center, Heart Institute, Los Angeles, United States of America
| |
Collapse
|
31
|
Kubo S, Kadota K. P3575Procedural and angiographic outcomes of main-branch stenting with side-branch drug-coated balloon inflation strategy for bifurcation lesions. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- S Kubo
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| |
Collapse
|
32
|
Sabbah M, Kadota K, Tada T, Kubo S, Hyodo Y, Otsuru S, Habara S, Tanaka H, Fuku Y, Goto T. P752Clinical and angiographic outcomes of true versus false lumen stenting of coronary chronic total occlusions: insights from intravascular ultrasound. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Sabbah
- Suez Canal University, Department of Cardiology, Ismailia, Egypt
| | - K Kadota
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Kurashiki, Japan
| | - Y Hyodo
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Otsuru
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Habara
- Kurashiki Central Hospital, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Kurashiki, Japan
| |
Collapse
|
33
|
Amano H, Kadota K, Kuwayama A, Miura K, Ohya M, Shimada T, Kubo S, Otsuru S, Habara S, Tada T, Tanaka H, Fuku Y, Goto T. P4560Long-term outcomes of iatrogenic coronary artery dissection during cardiac catheterization. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4560] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H Amano
- Kurashiki Central Hospital, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Kurashiki, Japan
| | - A Kuwayama
- Kurashiki Central Hospital, Kurashiki, Japan
| | - K Miura
- Kurashiki Central Hospital, Kurashiki, Japan
| | - M Ohya
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Otsuru
- Kurashiki Central Hospital, Kurashiki, Japan
| | - S Habara
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Kurashiki, Japan
| |
Collapse
|
34
|
Ohya M, Kuwayama A, Miura K, Shimada T, Murai R, Amano H, Kubo S, Otsuru S, Habara S, Tada T, Tanaka H, Fuku Y, Goto T, Kadota K. P3673In-hospital bleeding and utility of a maintenance dose of prasugrel 2.5 mg in high bleeding risk patients with acute coronary syndrome. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p3673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- M Ohya
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - A Kuwayama
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - K Miura
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - T Shimada
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - R Murai
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - H Amano
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - S Kubo
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - S Otsuru
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - S Habara
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - T Tada
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - H Tanaka
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - Y Fuku
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - T Goto
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| | - K Kadota
- Kurashiki Central Hospital, Cardiology Department, Kurashiki, Japan
| |
Collapse
|
35
|
Hishikawa N, Toyama S, Ikoma K, Taniguchi D, Kido M, Ohashi S, Kubo S, Maeda H, Sawada K, Mikami Y, Toshikazu K. ISPR8-0437/The abnormalities of the hip and knee joints in patients with posterior tibialis tendon dysfunction: Comparison with healthy age-matched controls. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.1053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
36
|
Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y. Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus 2018; 27:802-811. [DOI: 10.1177/0961203317749047] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Abstract
Objective We examined the efficacy and safety of rituximab in patients with refractory systemic lupus erythematosus (SLE). Methods The study enrolled 63 SLE patients who were treated with rituximab between 2002 and 2015. The participants underwent a battery of tests before treatment and at one year. Treatment ranged from two to four times at 500 or 1000 mg. Results Baseline characteristics were males:females = 6:57, age 33.9 years, and disease duration 87.2 months. The primary endpoint: The rate of major clinical response (MCR) was 60% while the partial clinical response (PCR) was 25%. Thirty of 36 (83%) patients with lupus nephritis (WHO II: 2, III: 5, IV: 22, V: 4, IV+V: 2, not assessed: 1) and 22 of 24 patients (92%) with neuropsychiatric SLE, who could be followed at one year, showed changes from BILAG A or B score to C or D score at one year. Multivariate analysis identified high anti-dsDNA antibody and shorter disease duration as significant determinants of MCR at one year. Repeat examination was conducted at five years. Primary failure was recorded in 8.8% and secondary failure in 32.4% (time to relapse: 24.4 months). Rituximab was well tolerated although 65 adverse events, mostly infections, were recorded within one year. Conclusion Rituximab is potentially efficacious for the treatment of patients with refractory SLE.
Collapse
Affiliation(s)
- S Iwata
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - K Saito
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - S Hirata
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - N Ohkubo
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - S Nakayamada
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - K Nakano
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - K Hanami
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - S Kubo
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - I Miyagawa
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - M Yoshikawa
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - Y Miyazaki
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - H Yoshinari
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| | - Y Tanaka
- The First Department of Internal Medicine, School of Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, Fukuoka, Japan
| |
Collapse
|
37
|
Satoh Y, Nakano K, Yoshinari H, Nakayamada S, Iwata S, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Saito K, Tanaka Y. A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab. Lupus 2018. [PMID: 29523055 DOI: 10.1177/0961203318762598] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
It has been reported that T helper 17 cells are involved in the pathogenesis of systemic lupus erythematosus, but there is no report on interleukin-17-targeted therapy. We report a case of a 62-year-old female who presented with psoriasis vulgaris and refractory lupus nephritis. Because her conditions were resistant to conventional treatment, and flow cytometry confirmed the proliferation of activated T helper 17 cells in peripheral blood, and examination of a renal biopsy tissue sample confirmed infiltration of numerous interleukin-17-positive lymphocytes to the renal interstitium, administration of the anti-interleukin-17A antibody secukinumab was initiated. After starting secukinumab the clinical and biological features were improved.
Collapse
Affiliation(s)
- Y Satoh
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - K Nakano
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - H Yoshinari
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - S Nakayamada
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - S Iwata
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - S Kubo
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - I Miyagawa
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - M Yoshikawa
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - Y Miyazaki
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - K Saito
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| | - Y Tanaka
- The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan
| |
Collapse
|
38
|
Nishikawa T, Miyamatsu N, Higashiyama A, Hojo M, Nishida Y, Fukuda S, Ichiura K, Kubo S, Okamura T. PO2-5DIFFERENCES IN DRINKING HISTORY BETWEEN HEALTHY PEOPLE AND PATIENTS WITH CEREBRAL INFARCTION. Alcohol Alcohol 2017. [DOI: 10.1093/alcalc/agx074.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Nomura E, Ohshita T, Naka H, Matsushima H, Kubo S, Takeshima S, Imamura E, Torii T, Hosomi N, Maruyama H, Matsumoto M. Stroke recurrence or death during 2 weeks after acute ischemic stroke with atrial fibrillation - multicenter prospective registry in Hiroshima –. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.1789] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Godai K, Miyamatsu N, Higashiyama A, Kubo S, Nishida Y, Sugiyama D, Nii Y, Tatsumi Y, Nishikawa T, Okamura T. PO3-2ALCOHOL CONSUMPTION AND PSYCHOLOGICAL DISTRESS IN HEALTHY JAPANESE RESIDENTS: THE KOBE STUDY. Alcohol Alcohol 2017. [DOI: 10.1093/alcalc/agx074.31] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Uemura J, Kitano T, Shiromoto T, Kubo S, Wada Y, Yagita Y. Assessment of carotid plaque characteristics by contrast-enhanced ultrasound in the long-term after neck radiotherapy. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Kariya T, Minami R, Imai T, Kubo S, Shimozuma T, Takahashi H, Yoshimura Y, Ito S, Mutoh T, Ota M, Endo Y, Sakamoto K. Development of Mega-Watt Gyrotrons for Fusion Research. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a11622] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Kariya
- Plasma Research Center (PRC), University of Tsukuha, Tsukuha, lharaki, 305-8577, Japan
| | - R. Minami
- Plasma Research Center (PRC), University of Tsukuha, Tsukuha, lharaki, 305-8577, Japan
| | - T. Imai
- Plasma Research Center (PRC), University of Tsukuha, Tsukuha, lharaki, 305-8577, Japan
| | - S. Kubo
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - H. Takahashi
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - S. Ito
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - M. Ota
- Plasma Research Center (PRC), University of Tsukuha, Tsukuha, lharaki, 305-8577, Japan
| | - Y. Endo
- Plasma Research Center (PRC), University of Tsukuha, Tsukuha, lharaki, 305-8577, Japan
| | - K. Sakamoto
- Japan Atomic Energy Agency (JAEA), Naka, lharaki, 311-0193, Japan
| |
Collapse
|
43
|
Imai T, Ichimura M, Nakashima Y, Katanuma I, Yoshikawa M, Kariya T, Minami R, Miyata Y, Yamaguchi Y, Ikezoe R, Shimozuma T, Kubo S, Yoshimura Y, Takahashi H, Mutoh T, Sakamoto K, Mizuguchi M, Ota M, Ozawa H, Hosoi K, Yaguchi F, Yonenaga R, Imai Y, Murakani T, Yagi K, Nakamura T, Aoki1 H, Iizumi H, Ishii T, Kondou H, Takeda H, Ichioka N, Masaki S, Yokoyama T. Status and Plan of GAMMA 10 Tandem Mirror Program. Fusion Science and Technology 2017. [DOI: 10.13182/fst11-a11563] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Imai
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Ichimura
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Nakashima
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - I. Katanuma
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Yoshikawa
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Kariya
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Minami
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Miyata
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Yamaguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Ikezoe
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Shimozuma
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - S. Kubo
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - Y. Yoshimura
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - H. Takahashi
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - T. Mutoh
- National Institute of Fusion Science(NIFS), Toki, Japan
| | - K. Sakamoto
- Japan Atomic Energy Research Institute(JAEA), Naka, Japan
| | - M. Mizuguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - M. Ota
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Ozawa
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - K. Hosoi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - F. Yaguchi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - R. Yonenaga
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - Y. Imai
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Murakani
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - K. Yagi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | | | - H. Aoki1
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Iizumi
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Ishii
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Kondou
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - H. Takeda
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - N. Ichioka
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - S. Masaki
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | - T. Yokoyama
- Plasma Research Center, University of Tsukuba, 305-8577 Tsukuba, Japan
| | | |
Collapse
|
44
|
Kariya T, Minami R, Imai T, Shimozuma T, Kubo S, Yoshimura Y, Takahashi H, Ito S, Mutoh T, Nakabayashi H, Eguchi T, Numakura T, Endo Y, Mitsunaka Y, Sakamoto K. Development of 154 GHz 1 MW Gyrotron for ECRH of LHD. Fusion Science and Technology 2017. [DOI: 10.13182/fst13-a16923] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- T. Kariya
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - R. Minami
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - T. Imai
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - T. Shimozuma
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - S. Kubo
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - Y. Yoshimura
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - H. Takahashi
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - S. Ito
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - T. Mutoh
- National Institute for Fusion Science (NIFS), Toki, Gifu, 509-5292, Japan
| | - H. Nakabayashi
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - T. Eguchi
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - T. Numakura
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - Y. Endo
- Plasma Research Center (PRC), University of Tsukuba, Tsukuba, Ibaraki, 305-8577, Japan
| | - Y. Mitsunaka
- Toshiba Electron Tubes & Devices Co., Ltd. (TETD), Otawara, Tochigi, 324-8550, Japan
| | - K. Sakamoto
- Japan Atomic Energy Agency (JAEA), Naka, Ibaraki, 311-0193, Japan
| |
Collapse
|
45
|
Tatematsu Y, Saito T, Ikegami H, Sekine T, Nagai D, Nozaki K, Ishii K, Kohagura J, Nakashima Y, Kubo S, Shimozuma T, Cho T. Experiment of Fundamental ECRH in the GAMMA 10 Central Cell. Fusion Science and Technology 2017. [DOI: 10.13182/fst05-a656] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- Y. Tatematsu
- Plasma Research Center, University of Tsukuba, Ibaraki 305-8577, Japan
| | - T. Saito
- Plasma Research Center, University of Tsukuba, Ibaraki 305-8577, Japan
| | - H. Ikegami
- Plasma Research Center, University of Tsukuba, Ibaraki 305-8577, Japan
| | - T. Sekine
- Plasma Research Center, University of Tsukuba, Ibaraki 305-8577, Japan
| | - D. Nagai
- Plasma Research Center, University of Tsukuba, Ibaraki 305-8577, Japan
| | - K. Nozaki
- Plasma Research Center, University of Tsukuba, Ibaraki 305-8577, Japan
| | - K. Ishii
- Plasma Research Center, University of Tsukuba, Ibaraki 305-8577, Japan
| | - J. Kohagura
- Plasma Research Center, University of Tsukuba, Ibaraki 305-8577, Japan
| | - Y. Nakashima
- Plasma Research Center, University of Tsukuba, Ibaraki 305-8577, Japan
| | - S. Kubo
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Shimozuma
- National Institute for Fusion Science, Toki, Gifu 509-5292, Japan
| | - T. Cho
- Plasma Research Center, University of Tsukuba, Ibaraki 305-8577, Japan
| |
Collapse
|
46
|
Shimada T, Kadota K, Miura K, Ohya M, Amano H, Kubo S, Otsuru S, Habara S, Tada T, Tanaka H, Fuku Y, Katoh H, Goto T. P525Midterm angiographic outcomes after drug-eluting stent implantation following rotational atherectomy. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Kubo S, Hussaini A, Kar S. P1371Incidence, predictors, and clinical impact of major bleeding events after transcatheter mitral valve edge-to-edge repair. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Amano H, Kadota K, Miura K, Ohya M, Shimada T, Kubo S, Hyodo Y, Otsuru S, Habara S, Tada T, Tanaka H, Fuku Y, Goto T. P3299Clinical curse of iatrogenic aortic dissection during coronary catheterization. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Miura K, Tada T, Habara S, Kuwayama A, Ohya M, Shimada T, Amano H, Kubo S, Hyodo Y, Otsuru S, Tanaka H, Fuku Y, Goto T, Kadota K. P521Different impact of morphological characteristics and stent expansion on restenosis after paclitaxel-coated balloon angioplasty for first- and second-generation drug-eluting stent restenosis. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p521] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Kubo S, Ohya M, Shimada T, Miura K, Amano H, Otsuru S, Tada T, Habara S, Tanaka H, Fuku Y, Goto T, Kadota K. P1379Impact of new lesion revascularization on very long-term serial luminal changes in sirolimus-eluting stent implanted lesions. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p1379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|